Skip Navigation

European Heart Journal 1992 13(2):149-151;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by DUPREZ, D.
Right arrow Articles by CLEMENT, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DUPREZ, D.
Right arrow Articles by CLEMENT, D. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

Medical treatment of peripheral vascular disease: good or bad?

D. DUPREZ and D. L. CLEMENT

Department of Cardiovascular Diseases, University Hospital Gent, Belgium

Received 10 December 1990; revised 4 March 1991; .

Correspondence. Dr Daniel Duprez, Department of Cardiovascular Diseases, University Hospital, De Pintelaan 185, 9000 Gent, Belgium

Abstract

The majority of patients with intermittent claudication are treated conservatively; smoking must be stopped and exercise therapy commenced. There are various classes of drugs that are widely prescribed for the treatment of peripheral vascular disease. in this editorial the medical treatment of peripheral vascular disease is claimed to achieve at least one of three goals: (1) improvement ofthefunctional capability; (2) inhibition of the progression of the atherosclerotic and anatomical lesions; (3) reduction of the cardiac and cerebro vascular morbidity and mortality. Guidelines are given for well controlled trials for newly developed drugs for the treatment of peripheral vascular disease in the future.

Key Words: Aspirin • dipyridamole • intermittent claudication • ketanserin • pentoxifylline • peripheral vascular disease • vasoactive drugs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
M. Ho, D. Veale, C. Eastmond, G. Nuki, and J. Belch
Macrovascular disease and systemic sclerosis
Ann Rheum Dis, January 1, 2000; 59(1): 39 - 43.
[Abstract] [Full Text]

Home page
 CirculationHome page
J.J.F. Belch, P.R.F. Bell, D. Creissen, J.A. Dormandy, R.C. Kester, R.D. McCollum, Y. Mizushima, C.V. Ruckley, J.H. Scurr, and J.H.N. Wolfe
Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1 Prodrug, in Patients With Intermittent Claudication
Circulation, May 6, 1997; 95(9): 2298 - 2302.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.